Naoki Kohei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naoki Kohei has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Koji Yoshimura
Department of Urology, Shizuoka General Hospital, Shizuoka, Japan
2 shared publications- Akito Terai
Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan
1 shared publication Ichiro Chihara
Department of Urology, Shizuoka General Hospital, Shizuoka, Japan
1 shared publication- Kazunari Tanabe
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
1 shared publication - Kazuya Omoto
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan
1 shared publication Kengo Sakaguchi
Department of Applied Biology, Faculty of Science and Technology Tokyo University of Science Chiba Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by SAGE Publications in Sage Open Medicine
- Vol. 6
Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
Objectives: To evaluate the impact of relative dose intensity for gemcitabine–cisplatin chemotherapy in patients with metastatic urothelial carcinoma. Methods: We retrospectively reviewed the medical records of 18 patients with metastatic urothelial carcinoma, who received gemcitabine–cisplatin regimen as the first-line chemotherapy between 2009 and 2015. The doses of gemcitabine and cisplatin were reduced or the intervals between treatment cycles were prolonged according to the treatment efficacy and adverse events during the first and second cycles. The individually optimal relative dose intensity was set as the actual dose per the standard dose in the first and second cycles. From the third course onward, patients received the gemcitabine–cisplatin chemotherapy with the same relative dose intensity. Overall survival was compared with the groups according to the value of relative dose intensity. Results: The median age was 72.5 (range, 56–79) years and 15 men and 3 women were enrolled in the study. The median number of cycles of first-line gemcitabine–cisplatin chemotherapy was 8 (range, 2–17), and the median survival time from initiation of first-line chemotherapy was 20.1 (range, 3.5–32.8) months. The total median relative dose intensity of gemcitabine–cisplatin chemotherapy was 56.1%. The median survival time of 10 patients in the group with the relative dose intensity of less than 60% was significantly longer than that of 8 patients in the group with the relative dose intensity of more than 60% (19.2 and 11.0 months, respectively, p = 0.04). Conclusion: Individual low relative dose intensity management in the first-line gemcitabine–cisplatin chemotherapy may be an acceptable option for patients with metastatic urothelial carcinoma.
- 1 January 2018
- Published by SAGE Publications in Sage Open Medicine
- Vol. 6
Open AccessImpact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
Objectives: To evaluate the impact of relative dose intensity for gemcitabine–cisplatin chemotherapy in patients with metastatic urothelial carcinoma. Methods: We retrospectively reviewed the medical records of 18 patients with metastatic urothelial carcinoma, who received gemcitabine–cisplatin regimen as the first-line chemotherapy between 2009 and 2015. The doses of gemcitabine and cisplatin were reduced or the intervals between treatment cycles were prolonged according to the treatment efficacy and adverse events during the first and second cycles. The individually optimal relative dose intensity was set as the actual dose per the standard dose in the first and second cycles. From the third course onward, patients received the gemcitabine–cisplatin chemotherapy with the same relative dose intensity. Overall survival was compared with the groups according to the value of relative dose intensity. Results: The median age was 72.5 (range, 56–79) years and 15 men and 3 women were enrolled in the study. The median number of cycles of first-line gemcitabine–cisplatin chemotherapy was 8 (range, 2–17), and the median survival time from initiation of first-line chemotherapy was 20.1 (range, 3.5–32.8) months. The total median relative dose intensity of gemcitabine–cisplatin chemotherapy was 56.1%. The median survival time of 10 patients in the group with the relative dose intensity of less than 60% was significantly longer than that of 8 patients in the group with the relative dose intensity of more than 60% (19.2 and 11.0 months, respectively, p = 0.04). Conclusion: Individual low relative dose intensity management in the first-line gemcitabine–cisplatin chemotherapy may be an acceptable option for patients with metastatic urothelial carcinoma.
- Open Access
- 17 March 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (6) , 590-595
Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer
Objectives: To examine the effects of combined treatment with sulfoquinovosylacylpropanediol and X‐ray irradiation on the remodeling of the prostate cancer microenvironment, including angiogenic and hypoxic characteristics.Methods: Human prostate cancer cells (DU145 and PC3) were implanted subcutaneously into the right hind legs of athymic nude mice. After the tumor volume reached 100–300mm3, 2mg/kg/day sulfoquinovosylacylpropanediol was given intravenously from day0 to day4, and cells were exposed to 4Gy X‐ray irradiation on days0 and 3 (for a total of 8Gy). Tumors were fixed and stained for pathological analyses and immunohistochemical evaluations. To analyze vascular normalization, 60mg/kg pimonidazole dissolved in saline was injected intraperitoneally.Results: Combined treatment with sulfoquinovosylacylpropanediol plus X‐ray irradiation enhanced growth inhibition in DU145 xenografts. The tumor vessel density in DU145 cells significantly decreased after the combined treatment. Staining for αsmooth muscle actin in vessels was significantly increased. Pimonidazole staining, showing hypoxic lesions, was negative from 72h, but positive at 6 and 24h after the first combined treatment. In contrast, no enhancement of the microenvironment in PC3 xenografts was observed with sulfoquinovosylacylpropanediol plus X‐ray irradiation.Conclusion: Sulfoquinovosylacylpropanediol could be a novel potent radiosensitizing agent targeting angiogenesis in prostate cancer.
- 17 March 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (6) , 590-595
Open AccessSulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer
Objectives: To examine the effects of combined treatment with sulfoquinovosylacylpropanediol and X‐ray irradiation on the remodeling of the prostate cancer microenvironment, including angiogenic and hypoxic characteristics.Methods: Human prostate cancer cells (DU145 and PC3) were implanted subcutaneously into the right hind legs of athymic nude mice. After the tumor volume reached 100–300mm3, 2mg/kg/day sulfoquinovosylacylpropanediol was given intravenously from day0 to day4, and cells were exposed to 4Gy X‐ray irradiation on days0 and 3 (for a total of 8Gy). Tumors were fixed and stained for pathological analyses and immunohistochemical evaluations. To analyze vascular normalization, 60mg/kg pimonidazole dissolved in saline was injected intraperitoneally.Results: Combined treatment with sulfoquinovosylacylpropanediol plus X‐ray irradiation enhanced growth inhibition in DU145 xenografts. The tumor vessel density in DU145 cells significantly decreased after the combined treatment. Staining for αsmooth muscle actin in vessels was significantly increased. Pimonidazole staining, showing hypoxic lesions, was negative from 72h, but positive at 6 and 24h after the first combined treatment. In contrast, no enhancement of the microenvironment in PC3 xenografts was observed with sulfoquinovosylacylpropanediol plus X‐ray irradiation.Conclusion: Sulfoquinovosylacylpropanediol could be a novel potent radiosensitizing agent targeting angiogenesis in prostate cancer.
- Open Access
- 17 July 2006
- Published by Wiley in International Journal of Urology
- Vol. 13 (7) , 891-895
Clinical outcome of tubeless cutaneous ureterostomy by the Toyoda method
Aim: Cutaneous ureterostomy is the least invasive method of urinary diversion, but it carries a risk of stomal stenosis. We retrospectively examined the long‐term outcome of tubeless cutaneous ureterostomy by the Toyoda method. Methods: Since 1983, the Toyoda cutaneous ureterostomy has been performed in 97 patients (169 renal units) with a minimum follow up of 3 months. The ureteral patency rate was reviewed according to whether the stomal type was single (one ureter, one stoma) or double‐barrel (two ureters, one stoma). Results: After a median follow up of 23 months (range 3 to 169), a tubeless condition was achieved in 102 (82%) of 124 renal units associated with double‐barrel stoma and in 35 (78%) of 45 renal units associated with single stoma. Although mild to moderate hydronephrosis was observed in 19% of patients, serum creatinine levels did not change after a minimum of 12 months after surgery (median 35). Conclusions: A high ureteral patency rate was achieved with cutaneous ureterostomy using the Toyoda method. This procedure, especially double‐barrel stomal creation, is a reasonable alternative to other forms of urinary diversion in patients at high risk.
- 17 July 2006
- Published by Wiley in International Journal of Urology
- Vol. 13 (7) , 891-895
Open AccessClinical outcome of tubeless cutaneous ureterostomy by the Toyoda method
Aim: Cutaneous ureterostomy is the least invasive method of urinary diversion, but it carries a risk of stomal stenosis. We retrospectively examined the long‐term outcome of tubeless cutaneous ureterostomy by the Toyoda method. Methods: Since 1983, the Toyoda cutaneous ureterostomy has been performed in 97 patients (169 renal units) with a minimum follow up of 3 months. The ureteral patency rate was reviewed according to whether the stomal type was single (one ureter, one stoma) or double‐barrel (two ureters, one stoma). Results: After a median follow up of 23 months (range 3 to 169), a tubeless condition was achieved in 102 (82%) of 124 renal units associated with double‐barrel stoma and in 35 (78%) of 45 renal units associated with single stoma. Although mild to moderate hydronephrosis was observed in 19% of patients, serum creatinine levels did not change after a minimum of 12 months after surgery (median 35). Conclusions: A high ureteral patency rate was achieved with cutaneous ureterostomy using the Toyoda method. This procedure, especially double‐barrel stomal creation, is a reasonable alternative to other forms of urinary diversion in patients at high risk.